Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
<h4>Background</h4>Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated.<h4>Objective</h4>To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune ch...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0255716 |
| _version_ | 1818722368509444096 |
|---|---|
| author | Náthali Felícia Mineiro Dos Santos Garrett Ana Cristina Carvalho da Costa Elaine Barros Ferreira Giovanni Damiani Paula Elaine Diniz Dos Reis Christiane Inocêncio Vasques |
| author_facet | Náthali Felícia Mineiro Dos Santos Garrett Ana Cristina Carvalho da Costa Elaine Barros Ferreira Giovanni Damiani Paula Elaine Diniz Dos Reis Christiane Inocêncio Vasques |
| author_sort | Náthali Felícia Mineiro Dos Santos Garrett |
| collection | DOAJ |
| description | <h4>Background</h4>Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated.<h4>Objective</h4>To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy.<h4>Materials and methods</h4>We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data.<h4>Results</h4>A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%).<h4>Conclusion</h4>The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors. |
| first_indexed | 2024-12-17T20:53:31Z |
| format | Article |
| id | doaj.art-ae5c174a354c41debb661420ffeed84d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T20:53:31Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ae5c174a354c41debb661420ffeed84d2022-12-21T21:32:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01168e025571610.1371/journal.pone.0255716Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.Náthali Felícia Mineiro Dos Santos GarrettAna Cristina Carvalho da CostaElaine Barros FerreiraGiovanni DamianiPaula Elaine Diniz Dos ReisChristiane Inocêncio Vasques<h4>Background</h4>Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated.<h4>Objective</h4>To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy.<h4>Materials and methods</h4>We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data.<h4>Results</h4>A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%).<h4>Conclusion</h4>The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors.https://doi.org/10.1371/journal.pone.0255716 |
| spellingShingle | Náthali Felícia Mineiro Dos Santos Garrett Ana Cristina Carvalho da Costa Elaine Barros Ferreira Giovanni Damiani Paula Elaine Diniz Dos Reis Christiane Inocêncio Vasques Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLoS ONE |
| title | Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. |
| title_full | Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. |
| title_fullStr | Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. |
| title_full_unstemmed | Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. |
| title_short | Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. |
| title_sort | prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0255716 |
| work_keys_str_mv | AT nathalifeliciamineirodossantosgarrett prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT anacristinacarvalhodacosta prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT elainebarrosferreira prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT giovannidamiani prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT paulaelainedinizdosreis prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT christianeinocenciovasques prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis |